Synergic fabrication of arsenic and anticancer drug-loaded ZIF-8 nanocomposites for improved radiofrequency ablation of liver metastasis cancer therapy

IF 2.9 4区材料科学 Q3 MATERIALS SCIENCE, MULTIDISCIPLINARY Materials Technology Pub Date : 2023-10-26 DOI:10.1080/10667857.2023.2243582

Dongwen Rong, Junmei Jia, Haile Qiu, Yanyan Liu, Chenan Liu, Xiaoyuan Wei

{"title":"Synergic fabrication of arsenic and anticancer drug-loaded ZIF-8 nanocomposites for improved radiofrequency ablation of liver metastasis cancer therapy","authors":"Dongwen Rong, Junmei Jia, Haile Qiu, Yanyan Liu, Chenan Liu, Xiaoyuan Wei","doi":"10.1080/10667857.2023.2243582","DOIUrl":null,"url":null,"abstract":"ABSTRACT Clinical treatment of hepatocellular carcinoma (HCC) is notoriously tricky because radiofrequency ablation (RFA) might encourage metastasis of remaining HCC. . The therapeutic efficacy of arsenic (A) and promising anticancer drug gemcitabine (G)-loaded zeolitic imidazolate framework-8 nanocomposites (AG@ZIF-8 NCs) on tumour remnants wasinvestigated. Results demonstrated that RFA significantly increased proliferation, induced metastasis, and triggered angiogenesis in recurrent tumours. We show that significant angiogenesis following RFA can increase the enhanced permeability and retention (EPR) effects and emphasize ZIF-8 carriers in recurrent tumours. e effectively fabricated biocompatible AG@ZIF-8 NCs. And they were superior to free gemcitabine in inhibiting cell proliferations, inducing apoptosis, blocking cell invasion and migration, and reversing in vitro EMT following sublethal heat treatment. In addition, AG@ZIF-8 NCs showed significantly improved therapeutic efficiency by reducing residual tumour development and in vivo metastasis compared to free gemcitabine. This study establishes a new standard for managing HCC that persists after RFA.","PeriodicalId":18270,"journal":{"name":"Materials Technology","volume":"12 4","pages":"0"},"PeriodicalIF":2.9000,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Materials Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/10667857.2023.2243582","RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MATERIALS SCIENCE, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

ABSTRACT Clinical treatment of hepatocellular carcinoma (HCC) is notoriously tricky because radiofrequency ablation (RFA) might encourage metastasis of remaining HCC. . The therapeutic efficacy of arsenic (A) and promising anticancer drug gemcitabine (G)-loaded zeolitic imidazolate framework-8 nanocomposites (AG@ZIF-8 NCs) on tumour remnants wasinvestigated. Results demonstrated that RFA significantly increased proliferation, induced metastasis, and triggered angiogenesis in recurrent tumours. We show that significant angiogenesis following RFA can increase the enhanced permeability and retention (EPR) effects and emphasize ZIF-8 carriers in recurrent tumours. e effectively fabricated biocompatible AG@ZIF-8 NCs. And they were superior to free gemcitabine in inhibiting cell proliferations, inducing apoptosis, blocking cell invasion and migration, and reversing in vitro EMT following sublethal heat treatment. In addition, AG@ZIF-8 NCs showed significantly improved therapeutic efficiency by reducing residual tumour development and in vivo metastasis compared to free gemcitabine. This study establishes a new standard for managing HCC that persists after RFA.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

协同制备砷和抗癌药物负载的ZIF-8纳米复合材料用于肝转移癌的射频消融治疗

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Materials Technology 工程技术-材料科学：综合

CiteScore

6.00

自引率

9.70%

发文量

105

审稿时长

8.7 months

期刊介绍： Materials Technology: Advanced Performance Materials provides an international medium for the communication of progress in the field of functional materials (advanced materials in which composition, structure and surface are functionalised to confer specific, applications-oriented properties). The focus is on materials for biomedical, electronic, photonic and energy applications. Contributions should address the physical, chemical, or engineering sciences that underpin the design and application of these materials. The scientific and engineering aspects may include processing and structural characterisation from the micro- to nanoscale to achieve specific functionality.